Spotlight Therapeutics' cell|specific in vivo gene editing platform ...

Targeted delivery of CRISPR-Cas9 and transgenes enables ...

As genome engineering advances cell-based therapies, a versatile approach to introducing both CRISPR-Cas9 ribonucleoproteins (RNPs) and ...

CRISPR/Cas9 genome editing for tissue‐specific in vivo targeting

The therapeutic gene editing efficiency of the CRISPR/Cas9 sys- tem could be influenced by several factors, such as the target gene sequence, ...

Spotlight Therapeutics Inc. - BioCentury Company Profiles - BCIQ

Building programmable CRISPR platform, Spotlight aims at cancer targets with $36.5M series B ... A snapshot of the next iteration of gene and cell therapies, gene ...

Researchers Develop “In Vivo” Gene Editing Model for Blood ...

“In our study, we are providing a cell-specific targeted lipid nanoparticle encapsulating mRNA therapeutics/editors as a platform technology ...

Cell and gene therapy | Analytical assay development - Miltenyi Biotec

Our solutions are applicable for different kinds of cell and gene therapies spanning a variety of cell type–specific applications, including but not limited to ...

Spotlight on Umoja Biopharma's Engineered induced Pluripotent ...

... platform. While the cell therapy industry has demonstrated the transformative potential of using gene-engineered, patient-derived cells for treating specific ...

Gene Editing 101 - Front Line Genomics

an effective tool for generating site specific breaks within a cell's ... therapy is a ... experiments that hope to use gene editing tools in vivo, but there.

GMP Solutions for CGT - TheraPEAK ® Products - Lonza Bioscience

To maximize your chance of success, we've crafted a series of GMP solutions for cell and gene therapy based on these core principles. Using TheraPEAK® Products ...

CRISPR Medicine News, 4 December 2020 | Your missing links are ...

PBCAR0191 is under clinical development as an anti-CD19 CRISPR-engineered CAR T-cell therapy for relapsed/refractory Non-Hodgkin Lymphoma (NHL) ...

Spotlight Therapeutics Closes its Series A Financing Bringing the ...

... therapeutics for direct in vivo altering of target genes, clos ... Cell and Gene Therapy. Spotlight Therapeutics ... CRISPR genome editing ...

The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam ...

Casgevy is the first FDA-approved therapy utilizing CRISPR/Cas9, a type of genome editing technology where hematopoietic (blood) stem cells of ...

Gene therapy – the status quo and future trends - Mewburn Ellis

In addition to in-vivo gene therapy, CRISPR has been widely adopted by developers in the ex-vivo, cell-based gene therapy space and used to ...

Scaffold-mediated non-viral delivery platform for CRISPR/Cas9 ...

Genome editing, especially via the simple and versatile type II CRISPR/Cas9 system, offers an effective avenue to precisely control cell fate, an important ...

CRISPR/Cas9 Genome Editing for Tissue‐Specific In Vivo Targeting

gene editing therapy, base editing approaches for sickle cell dis- ease are in clinical trials developed by Beam Therapeutics with two different therapeutic ...

GSK signs strategic agreement to transfer rare disease gene therapy ...

Autologous ex vivo gene therapy is a novel personalised treatment approach that can be used to address rare genetic disorders using the ...

University of Pennsylvania Coverage - MedCity News

Data show early signs of efficacy for CRISPR-edited cell therapy in cancers ... A team at UPenn led by CAR-T pioneer Carl June used CRISPR/Cas9 to engineer T ...

Spotlight Therapeutics Inc. - BioWorld

Spotlight Therapeutics Inc., a company developing cell-targeted in vivo CRISPR gene editing biologics, has raised $36.5 million in series B ...

Spotlight Therapeutics - Overview, News & Similar companies

... cell-targeted in vivo CRISPR gene editing therapies. Spotlight's proprietary technology platform TAGE (Targeted Active Gene Editors) is a new class of ...

Takara Bio—Home

Takara Bio provides kits, reagents, instruments, and services that help researchers explore questions about gene discovery, regulation, and function.

Influence of Culture Conditions on Ex Vivo Expansion of T ... - Frontiers

In CAR T cell therapy, the T cells are genetically modified by transduction of a CAR transgene. The antigen-specific CAR construct is expressed on the surface ...